Capital Performance Advisors’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.4K | Hold |
25,976
| – | – | 0.01% | 268 |
|
|
2025
Q1 | $66.5K | Hold |
25,976
| – | – | 0.01% | 255 |
|
|
2024
Q4 | $48.8K | Hold |
25,976
| – | – | 0.02% | 161 |
|
|
2024
Q3 | $26.5K | Sell |
25,976
-817
| -3% | -$833 | 0.01% | 520 |
|
|
2024
Q2 | $31.3K | Buy |
26,793
+535
| +2% | +$626 | 0.01% | 90 |
|
|
2024
Q1 | $33.1K | Buy |
26,258
+283
| +1% | +$357 | 0.01% | 83 |
|
|
2023
Q4 | $46.2K | Buy |
25,975
+1
| +0% | +$2 | 0.02% | 76 |
|
|
2023
Q3 | $43.1K | Hold |
25,974
| – | – | 0.02% | 56 |
|
|
2023
Q2 | $51.9K | Hold |
25,974
| – | – | 0.03% | 59 |
|
|
2023
Q1 | $54.5K | Hold |
25,974
| – | – | 0.03% | 53 |
|
|
2022
Q4 | $35.6K | Hold |
25,974
| – | – | 0.02% | 50 |
|
|
2022
Q3 | $27K | Hold |
25,974
| – | – | 0.02% | 45 |
|
|
2022
Q2 | $28K | Buy |
+25,974
| New | +$28K | 0.02% | 46 |
|